Guskin Gold Corp. (GKIN) Files OTC Markets Application to List on the OTCQB®

Guskin Gold Corp
4 min read
0
In this article:

SAN JOSE, CA, July 28, 2021 (GLOBE NEWSWIRE) -- Guskin Gold Corp. (the “Company” or “Guskin Gold”) (OTC: GKIN), a company focused on acquiring and advancing gold properties in the world’s seventh largest gold producing nation, Ghana, is pleased to advise the Company has filed an application with OTC Markets to up-list from Pink Sheet Current to the OTCQB.

The Company has worked over the past six months to implement the necessary financial and corporate governance needed to meet the listing qualifications as required by the OTCQB in order to up-list, and we believe that Guskin Gold’s approval is imminent following our latest submission.

The Company Board of Directors believe that the move to the OTCQB will provide enhanced investor benefits including higher reporting, compliance, and quality standards, greater access to analyst coverage and news services, and provides investors improved visibility to enhance trading decisions.

The OTCQB is recognized by the United States Securities and Exchange Commission (SEC) as an established public market providing public information for analysis and value of securities. The OTCQB marketplace is run through OTC Link, an inter-dealer quotation and trading system developed by OTC Markets Group and is registered with the SEC as a broker-dealer and as an Alternative Trading System (ATS).

"As we continue to grow our operations in Ghana our board of directors decided it would be in the best interest of the Company to up-list to the OTCQB. As we continue to expand our exploration and mining operations at the Kukuom Concession an up-list at this time increases our core value from a strategic, financing, and evaluation perspective.” states Mrs. Naana Asante, Guskin Gold CEO. “The OTCQB dramatically increases access to the retail investor community and visibility. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier. We are confident this will help create shareholder value should we be successful in our up-listing efforts.”

Guskin Gold’s operations are focused on gold exploration and alluvial mining in Ghana, the number one gold producer in Africa and seventh largest gold producing country in the world.

The Company’s operations are located in the highly renowned Sefwi-Bibiani gold belt, where known gold producers including Newmont, Kinross, Anglogold Ashanti, and Asanko Gold, and are all within 100km of the Kukuom project area. The Kukuom Concession covers a total surface area of 156 square kilometers and is located between the cities of Goaso and Bibiani in the Ahafo District of Ghana

For additional details see announcements of June 11, 2021 (Guskin Gold Announces Joint Venture Partnership Agreement with Africa Exploration and Minerals Group) and June 30, 2021 (Guskin Gold’s Initial Report on the Kukuom Concession Gold Project in Ghana, Africa).

About Guskin Gold Corp.
Guskin Gold Corp. (OTC: GKIN) is a junior mining company publicly traded in the United States, with its head office in Santa Clara, California. Guskin is focused on gold exploration and alluvial mining in Ghana, the number one gold producer in Africa and seventh largest gold producing country in the world. The company’s leadership team is world-class. Many are native to Ghana, all offer specialized expertise in the business of gold exploration, mining, public markets, and finance. And all are passionately committed to the success of the company, our partners, and investors. For additional information please visit www.guskingold.com.

Contact
Mrs. Naana Asante
Chief Executive Officer
Tel: + (408) 766-1511
naana.asante@guskingold.com

Forward-Looking Statements and Disclosure

The application process will not guarantee acceptance of Company’s application by OTC Markets from the Pink Sheet Current to OTCQB.

This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with the exploration and exploitation of the Kukuom Concession, new mineral and/or gold projects, securing necessary financing, the future of the U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations pertaining to the mining and exploration of mineral properties in Ghana and internationally. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.


Advertisement

Recommended Stories

  • Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

    Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnings figures on Thursday, the company’s shares fell sharply, giving it a market capitalization of about $95 billion. The problem for Bristol-Myers is that its older blockbuster products, cancer drug Revlimid and blood thinner Eliquis, are expected to decline in the coming years and investors aren’t convinced that the company has enough growth drivers in the near term.

  • Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?

    Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic. Is PFE stock a sell?

  • GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    (Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

  • Compared to Estimates, Hertz Global (HTZ) Q1 Earnings: A Look at Key Metrics

    The headline numbers for Hertz Global (HTZ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

  • Hertz Global Holdings, Inc. (HTZ) Reports Q1 Loss, Tops Revenue Estimates

    Hertz Global (HTZ) delivered earnings and revenue surprises of -184.44% and 2.83%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  • Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for

    Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics

    Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

  • Tired of Unreliable Dividends? Check Out These 4 High-Yield Alternatives

    Are you tired of relying solely on dividend stocks for passive income? While they can be a great source of cash flow, putting all your eggs in the stock market basket comes with serious risks. Just look at what happened with AT&T Inc. (NYSE:T) in ...

  • Analysis-NYCB faces tough choices on CRE loans, balance sheet diversification

    New York Community Bancorp will have to lure buyers for its commercial real estate (CRE) loans with steep discounts and diversify its revenue as it races to shore up its finances. The bank's new management has promised to unveil a turnaround plan this month after losses on CRE loans, NYCB's core business, sparked a rout that wiped nearly $6 billion off its market value and sparked ratings downgrades. A $1 billion investment led by former U.S. Treasury Secretary Steven Mnuchin's Liberty Strategic Capital has shored up the bank for the short-term, but it still needs to bolster its capital and shrink its exposure to the CRE sector, which has been hammered by higher interest rates.

  • Google owner worth more than $2 trillion after announcing first dividend

    Google’s parent company soared past a $2 trillion valuation last night as the search engine giant said it would pay a dividend for the first time.